BioMarin: Genzyme virus problem won

reason-splitting.blogspot.com
Genzyme (NASDAQ: GENZ) founde a virus strain and stopped productiobn of two drugs atthe Allston, Mass., The strain, Vesivirus 2117, apparently does not causd human infection but interrupts the growth of cellsd that are used to make Aldurazyme — a treatment for MPS I, a rare and fatapl disease caused by an enzyme deficiency was last filled at the Genzyme facility in Septembere 2008, according to BioMarin BMRN). The company has about 10 months of vialefd inventoryon hand, it said, and uses a second fill finishu supplier. A third supplier is expected to be qualifiedr laterthis year, BioMarin said. BioMari n makes the bulk material used in Aldurazyme at itsNovati facility.
The Food and Drug Administration hadinspected Genzyme’s planft in September and October and reportedly was concernedd about controls to protect against contamination.